Welcome to our dedicated page for Biotricity news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity stock.
Biotricity Inc. (OTCQB: BTCY) is a Nevada‑incorporated medical technology and Technology‑as‑a‑Service (TaaS) company that focuses on remote monitoring, diagnostic solutions, and chronic disease management, with a strong emphasis on cardiac care. This news page aggregates company announcements, financial updates, and operational developments related to BTCY.
Readers can follow earnings and financial results updates, where Biotricity discusses themes such as recurring technology fees, margins, operating efficiency, and the role of proprietary AI‑driven automation in its TaaS model. The company frequently issues press releases around quarterly and annual results, often accompanied by details of investor conference calls and webcasts.
News items also cover product and platform developments, including Biotricity’s Biocore suite of cardiac monitoring products, the Biocore Pro next‑generation cardiac monitoring device, and the Cardiac AI Cloud platform. Announcements have highlighted the use of large volumes of anonymized heartbeat data to support diagnostic accuracy and remote cardiac care.
Another important category of BTCY news involves strategic collaborations and partnerships. Examples include Biotricity’s collaboration with Health‑E Commerce to make its Bioheart 24/7 wearable cardiac monitoring solution available to FSA and HSA users, and its work with B‑Secur to expand a device‑neutral cardiac monitoring platform that integrates ECG data from consumer wearables into a cloud‑based medical workflow.
Investors and healthcare professionals can use this page to track Biotricity’s communications on remote patient monitoring, cardiac diagnostics, intellectual property milestones, and access to hospital networks and managed care channels. For those following BTCY, returning to this page provides a centralized view of the company’s latest public disclosures and press releases.
Biotricity (OTCQB:BTCY) reported Q3 fiscal 2026 results for the quarter ended December 31, 2025, showing continued revenue momentum and margin expansion.
Key metrics: revenue $4.0M (+10.2% YoY), gross margin 81.5%, recurring Technology Fees $3.6M (91.2% of revenue), and a reduced net loss of $1.1M.
Biotricity (OTCQB:BTCY) will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11, 2026 at 4:30 PM ET. The company reported continued revenue growth and achieved positive EBITDA, and management will provide remarks followed by a Q&A.
Webcast access begins 15 minutes early; a replay will be available through February 25, 2026 at 11:59 PM ET.
Biotricity (OTCQB:BTCY) reported second quarter fiscal 2026 results for the quarter ended September 30, 2025, highlighting revenue growth and margin expansion while maintaining a path toward scalable profitability.
Key figures: Revenue $3.9M (+19% YoY), Recurring technology fees $3.5M (88.7% of revenue), Gross margin 81.9% (vs. 75.3% prior year), and Net loss $0.77M or $0.03 per share (53.3% improvement YoY). The company cited AI-driven automation, Biocore Pro adoption, U.S. commercial expansion, and progress toward international regulatory clearances as drivers of efficiency and growth.
Biotricity (OTCQB: BTCY) will host its Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14, 2025 at 4:30 PM ET (1:30 PM PT). Management presenting will include Founder & CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou, followed by a Q&A for investors.
The live listen-only webcast begins 15 minutes before the call for registration. Dial-in numbers are provided for toll-free and international access, and a replay will be available about three hours after the live call via the company investor website until November 28, 2025 at 11:50 PM ET.
Biotricity (OTCQB:BTCY) has announced a strategic collaboration with Health-E Commerce, making its continuous cardiac monitoring device Bioheart available to over 70 million FSA and HSA users. The partnership enables consumers to use pre-tax healthcare funds for purchasing the 24/7 wearable heart monitoring solution through FSA Store and HSA Store.
Bioheart provides a 360-degree view of heart health by capturing data from three different angles, offering continuous monitoring during all activities including exercise and sleep. Users can request data review from healthcare professionals or cardiologists through the integrated app, transforming cardiac care from reactive to preventative.
Biotricity (OTCQB:BTCY) and B-Secur have announced a significant expansion of their cardiac monitoring platform to include consumer wearables integration. The device-neutral platform, initially launched in early 2025 for ambulatory cardiac monitoring, will now incorporate ECG data from smartwatches, smart rings, and fitness trackers.
The enhanced platform leverages B-Secur's FDA-cleared HeartKey® ECG algorithms to deliver medical-grade accuracy. This advancement enables seamless integration of consumer device data into regulated care pathways, bridging the gap between consumer wearables and clinical care. The initiative aims to address the growing global cardiovascular disease burden, which is projected to triple global costs to $1.8 trillion by 2050.
Biotricity (OTCQB:BTCY) reported strong Q1 FY2026 results, marking a significant milestone with its first-ever positive EBITDA of $333,337. Revenue grew 21% to $3.9 million, with recurring Technology-as-a-Service fees increasing 11.8% to $3.4 million. The company achieved an improved gross margin of 80.5%, up from 73.8% year-over-year.
Net loss significantly decreased to $0.75 million ($0.03 per share), an 80.6% improvement from the previous year. The company's strategic expansion now covers 70% of the US market, with partnerships giving access to 90% of all US hospitals. Biotricity's AI-driven Cardiac Cloud platform, leveraging over 2 trillion beats of anonymized data, is advancing towards FDA clearance.
Biotricity (OTCQB:BTCY), a Technology-as-a-Service healthcare company, will host its Fiscal 2026 First Quarter Financial Results conference call on August 14, 2025, at 4:30 PM ET. The company anticipates reporting continued revenue growth, margin improvements, enhanced operational efficiency, and notably, a shift to positive EBITDA.
CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will lead the presentation and Q&A session. Investors can access the call via toll-free numbers or a webcast, with replay available until August 28, 2025.
Biotricity (OTCQB:BTCY), a Technology-as-a-Service healthcare solutions provider, reported strong financial results for FY2025. The company achieved 14.3% revenue growth to $13.8 million, with significant margin improvement to 76.6% from 69.3% in the previous year.
Key highlights include a 24.5% reduction in operating expenses, negative EBITDA improvement of 63.9% to $3.2 million, and the company's first-ever positive Adjusted EBITDA of $438,260 in Q4-FY25. Recurring Technology Fees grew 12% YOY to $12.6 million, representing over 10.5 times Device Sales revenue. The company secured strategic partnerships with GPOs representing 90% of US hospitals and is pursuing FDA clearance for its AI clinical model.
Biotricity (OTCQB:BTCY), a Technology-as-a-Service healthcare company, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025, at 4:45 PM ET. The company anticipates announcing its best financial performance to date, including improvements in margins, operational efficiency, and a shift to positive adjusted EBITDA.
CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will lead the presentation followed by a Q&A session. The call will be accessible via webcast and toll-free numbers, with replay available until August 1, 2025.
FAQ
What is the current stock price of Biotricity (BTCY)?
What is the market cap of Biotricity (BTCY)?
